UK and Singapore launch a regulatory innovation corridor to speed up access to breakthrough health technologies

15th December 2025

UK and Singapore launch a regulatory innovation corridor to speed up access to breakthrough health technologies

Summary: On 12 December 2025, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and Singapore’s Health Sciences Authority (HSA) launched a regulatory innovation corridor — a collaborative pathway that allows developers to engage with both regulators at the same time. This corridor enables companies to seek early, informal joint advice on planning, clinical trial design and evidence requirements, reducing duplication and delays without compromising safety. It aims to accelerate patient access to breakthrough therapies in high-impact areas such as cancer, neurodegenerative diseases, obesity, rare diseases and advanced diagnostics.  Flagship Pioneering, a biotechnology innovation group, will be the first partner to use the corridor, helping shape how coordinated regulatory engagement works in practice.  The initiative also strengthens scientific cooperation on early diagnosis, prevention, healthy ageing and digital health, supporting broader national strategies like England’s 10-Year Health Plan and Singapore’s Healthier SG programme. 

Link: UK and Singapore launch a regulatory innovation corridor to speed up access to breakthrough health technologies

Back to Recent News